BioTech

Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)

Insys Therapeutics (NASDAQ:INSY) hit a new 52-week high during trading on Tuesday following a better than expected earnings announcement, AnalystRatings.NET reports. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was 21.73% in last session and finished the day at $83.37. Traded volume was 1,203,992 million shares in the last session and the average volume of the stock remained 263.48 million shares. The beta of the stock remained 2.46.

Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) stock rose 14 percent Tuesday after the company announced that federal regulators have lifted their clinical hold on its treatment for traumatic brain injuries. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) rose 14.52 percent to $7.10 yesterday on volume of 7.43 million shares. The intra-day range of the stock was $7.05 to $8.35. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) has a market capitalization of $75.43 million.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported a fourth quarter loss of 19 cents per share, much wider than the year-ago loss of 4 cents per share and the Zacks Consensus Estimate of a loss of 17 cents per share. Lower revenues and higher costs led to the year-over-year increase in loss. Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock on Mar 4, 2014 reported a increase of 8.16% to the closing price of $14.97. Its fifty two weeks range is $5.03 -$18.18. The total market capitalization recorded $1.82billion. The overall volume in the last trading session was 2,404,157million shares. In its share capital, Halozyme Therapeutics, Inc. (NASDAQ:HALO) has 112.77 million outstanding shares.

Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Tuesday, March 11, 2014 at 5:00 PM Eastern Time. On Tuesday, shares of Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) advanced 6.67% to close the day at $3.20. Company return on investment (ROI) is -97.30% and its monthly performance is recorded as 20.30%. Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) quarterly revenue growth is 17.65%.